Baseline characteristics of participants allocated to the VTP group or routine care plus individual voluntary use of mindfulness-based home exercises on CD
| All participants | VTP group | Control group | |
|---|---|---|---|
| (n=71) | (n=36) | (n=35) | |
| Demographics | |||
| Age, years | 53.9 (9.1) | 53.0 (9.4) | 54.9 (8.9) |
| Women | 56 (78.9) | 28 (77.8) | 28 (80.0) |
| Married/living with partner | 46 (64.8) | 23 (63.9) | 23 (65.7) |
| Education >12 years | 37 (52.1) | 18 (50.0) | 19 (54.3) |
| Paid work | 28 (39.4) | 14 (38.9) | 14 (40.0) |
| Disease and function | |||
| Disease duration, years | 16.2 (12.7) | 14.4 (11.3) | 18.0 (14.0) |
| Symptoms duration, years | 19.1 (12.8) | 18.7 (13.1) | 19.6 (12.7) |
| Diagnosis | |||
| Rheumatoid arthritis | 42 (59.2) | 23 (63.9) | 19 (54.3) |
| Ankylosing spondylitis | 15 (21.1) | 6 (16.7) | 9 (25.7) |
| Psoriatic arthritis | 7 (9.9) | 3 (8.3) | 4 (11.4) |
| Other inflammatory arthritis | 7 (9.8) | 4 (11.1) | 3 (8.7) |
| Comorbidity | 48 (72.7) | 26 (76.5) | 22 (68.8) |
| PGA (0–10, 0=no activity) | 4.6 (1.7) | 4.6 (1.6) | 4.5 (1.9) |
| Medication | |||
| Analgesics | 35 (49.3) | 19 (52.8) | 16 (45.7) |
| NSAIDs | 33 (46.5) | 20 (55.6) | 13 (37.1) |
| Cortisone | 26 (36.6) | 14 (38.9) | 12 (34.3) |
| DMARDs (non-biological) | 34 (47.9) | 18 (50.0) | 16 (45.7) |
| Biological therapy | 19 (26.8) | 7 (19.4) | 12 (34.3) |
| GHQ-20 >23 | 23 (32.4) | 13 (36.1) | 10 (28.6) |
| MHAQ (0–3, 0=good function) | 0.5 (0.5) | 0.4 (0.3) | 0.6 (0.7) |
| Physical activity>2 h/week | 25 (35.2) | 14 (38.9) | 11 (31.4) |
Values are reported as number (%) or mean (SD).
CD, control group; DMARDs, disease-modifying antirheumatic drugs; GHQ-20, General Health Questionnaire-20; MHAQ, Modified Health Assessment Questionnaire; NSAIDs, non-steroidal anti-inflammatory drugs; PGA, patient global assessment of disease activity; VTP, Vitality Training Programme.